Home Medicine The BACH project protocol: an international multicentre total Bile Acid Comparison and Harmonisation project and sub-study of the TURRIFIC randomised trial
Article
Licensed
Unlicensed Requires Authentication

The BACH project protocol: an international multicentre total Bile Acid Comparison and Harmonisation project and sub-study of the TURRIFIC randomised trial

  • Corey Markus ORCID logo EMAIL logo , Suzette Coat ORCID logo , Hanns-Ulrich Marschall ORCID logo , Catherine Williamson ORCID logo , Peter Dixon ORCID logo , Maria Fuller ORCID logo , Susan Matthews ORCID logo , Wayne Rankin ORCID logo , Michael Metz and William M. Hague ORCID logo
Published/Copyright: August 6, 2021

Abstract

Objectives

Multicentre international trials relying on diagnoses derived from biochemical results may overlook the importance of assay standardisation from the participating laboratories. Here we describe a study protocol aimed at harmonising results from total bile acid determinations within the context of an international randomised controlled Trial of two treatments, URsodeoxycholic acid and RIFampicin, for women with severe early onset Intrahepatic Cholestasis of pregnancy (TURRIFIC), referred to as the Bile Acid Comparison and Harmonisation (BACH) study, with the aims of reducing inter-laboratory heterogeneity in total bile acid assays.

Methods

We have simulated laboratory data to determine the feasibility of total bile acid recalibration using a reference set of patient samples with a consensus value approach and subsequently used regression-based techniques to transform the data.

Results

From these simulations, we have demonstrated that mathematical recalibration of total bile acid results is plausible, with a high probability of successfully harmonising results across participating laboratories.

Conclusions

Standardisation of bile acid results facilitates the commutability of laboratory results and collation for statistical analysis. It may provide the momentum for broader application of the described techniques in the setting of large-scale multinational clinical trials dependent on results from non-standardised assays.


Dedicated to the Memory of Dr Michael Metz. It is with great sadness that we dedicate this manuscript to the memory of the late Dr Michael Metz, whom many will have known through his international activities in the field of paediatric and obstetric clinical chemistry. Michael was incredibly passionate about paediatric and obstetric laboratory medicine and was highly regarded for his commitment to patient care and teaching. The genesis of this harmonisation project arose from his interest in the medicine of ICP. Michael was an active committee member and chaired the South Australian/Northern Territory Australasian Association of Clinical Biochemists (AACB) branch for over 10 years, while internationally he was an elected member of the International Federation of Clinical Chemistry: Task Force on Paediatric Laboratory Medicine. He was a member of the advisory board of the Atherosclerosis Australasia Familial Hypercholesterolaemia Registry and sole consultant for the lipid clinic at the Adelaide Women’s and Children’s Hospital. Michael was also known for his warm generous nature and sense of humour. Michael is profoundly missed by all his colleagues and friends. Vale Michael!



Corresponding author: Corey Markus, Automated Laboratory, SA Pathology, GPO Box 2100, Adelaide, SA, 5001, Australia; and Flinders University International Centre for Point-of-Care Testing, Flinders Health and Medical Research Institute, Sturt Road, Bedford Park, SA, 5042, Australia, Email:

Michael Metz deceased


Funding source: Australasian Association of Clinical Biochemists (AACB)

Acknowledgments

We gratefully acknowledge the Australasian Association of Clinical Biochemists (AACB) in agreeing to provide financial support for transportation of BACH samples to participating laboratories servicing Australian TURRIFIC trial recruitment sites.

  1. Research funding: None declared.

  2. Author contributions: MM, WH, MF and CM conceived the requirement for harmonisation of total bile acids. CM, WR, SM and WH were involved in the experimental design and questionnaire. CM performed the simulation, summary statistical results and produced the graphical output. WH, SC, H-UM and CW are contributing to subject recruitment for the TURRIFIC study and, together with PD, are providing linkage to participating international laboratories. CM drafted the original manuscript. All authors have read and approved the final manuscript.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals providing samples for this study.

  5. Ethical approval: Ethical approval for the study has been granted by the Women’s and Children’s Hospital Human Research Ethics Committee (HREC/18/WCHN/36).

References

1. de Aguiar Vallim, TQ, Tarling, EJ, Edwards, PA. Pleiotropic roles of bile acids in metabolism. Cell Metabol 2013;17:657–69.10.1016/j.cmet.2013.03.013Search in Google Scholar

2. Wahlström, A, Sayin, SI, Marschall, H-U, Bäckhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metabol 2016;24:41–50. https://doi.org/10.1016/j.cmet.2016.05.005.Search in Google Scholar

3. Pataia, V, Dixon, PH, Williamson, C. Pregnancy and bile acid disorders. Am J Physiol Gastrointest Liver Physiol 2017;313:G1–6. https://doi.org/10.1152/ajpgi.00028.2017.Search in Google Scholar

4. Ovadia, C, Seed, PT, Sklavounos, A, Geenes, V, Di Ilio, C, Chambers, J, et al.. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet 2019;393:899–909. https://doi.org/10.1016/s0140-6736(18)31877-4.Search in Google Scholar

5. Glantz, A, Marschall, H-U, Mattsson, L-Å. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology 2004;40:467–74. https://doi.org/10.1002/hep.20336.Search in Google Scholar

6. Kawakita, T, Parikh, LI, Ramsey, PS, Huang, C-C, Zeymo, A, Fernandez, M, et al.. Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol 2015;213:570.e1–8. https://doi.org/10.1016/j.ajog.2015.06.021.Search in Google Scholar

7. Marathe, JA, Lim, WH, Metz, MP, Scheil, W, Dekker, GA, Hague, WM. A retrospective cohort review of intrahepatic cholestasis of pregnancy in a South Australian population. Eur J Obstet Gynecol Reprod Biol 2017;218:33–8. https://doi.org/10.1016/j.ejogrb.2017.09.012.Search in Google Scholar

8. Walker, IA, Nelson-Piercy, C, Williamson, C. Role of bile acid measurement in pregnancy. Ann Clin Biochem 2002;39:105–13. https://doi.org/10.1258/0004563021901856.Search in Google Scholar

9. Hague, WM, Callaway, L, Chambers, J, Chappell, L, Coat, S, de Haan-Jebbink, J, et al.. A multi-centre, open label, randomised, parallel-group, superiority trial to compare the efficacy of ursodeoxycholic acid with rifampicin in the management of women with severe early onset intrahepatic cholestasis of pregnancy: the TURRIFIC randomised trial. BMC Pregnancy Childbirth 2021;21:51. https://doi.org/10.1186/s12884-020-03481-y.Search in Google Scholar

10. Ducroq, DH, Morton, MS, Shadi, N, Fraser, HL, Strevens, C, Morris, J, et al.. Analysis of serum bile acids by isotope dilution-mass spectrometry to assess the performance of routine total bile acid methods. Ann Clin Biochem 2010;47:535–40. https://doi.org/10.1258/acb.2010.010154.Search in Google Scholar

11. Heikkinen, J. Serum bile acids in the early diagnosis of intrahepatic cholestasis of pregnancy. Obstet Gynecol 1983;61:581–7.Search in Google Scholar

12. Danese, E, Salvagno, GL, Negrini, D, Brocco, G, Montagnana, M, Lippi, G. Analytical evaluation of three enzymatic assays for measuring total bile acids in plasma using a fully-automated clinical chemistry platform. van Veen HW, editor. PloS One 2017;12:e0179200. https://doi.org/10.1371/journal.pone.0179200.Search in Google Scholar

13. Vesper, HW, Myers, GL, Miller, WG. Current practices and challenges in the standardization and harmonization of clinical laboratory tests. Am J Clin Nutr 2016;104(3 Suppl):907S–12S. https://doi.org/10.3945/ajcn.115.110387.Search in Google Scholar

14. Lee, SG, Chung, H-J, Park, JB, Park, H, Lee, EH. Harmonization of laboratory results by data adjustment in multicenter clinical trials. Korean J Intern Med 2018;33:1119–28. https://doi.org/10.3904/kjim.2017.034.Search in Google Scholar

15. Linnet, K. Necessary sample size for method comparison studies based on regression analysis. Clin Chem 1999;45:882–94. https://doi.org/10.1093/clinchem/45.6.882.Search in Google Scholar

16. Linnet, K. Performance of Deming regression analysis in case of misspecified analytical error ratio in method comparison studies. Clin Chem 1998;44:1024–31. https://doi.org/10.1093/clinchem/44.5.1024.Search in Google Scholar

17. Stöckl, D, Van Uytfanghe, K, Van Aelst, S, Thienpont, LM. A statistical basis for harmonization of thyroid stimulating hormone immunoassays using a robust factor analysis model. Clin Chem Lab Med 2014;52:965–72http://www.degruyter.com/view/j/cclm.2014.52.issue-7/cclm-2013-1038/cclm-2013-1038.xml.10.1515/cclm-2013-1038Search in Google Scholar PubMed

18. Cross, Validated. Can averaging the variables be seen as a crude form of PCA? [Internet]. Available from: https://stats.stackexchange.com/questions/93905/can-averaging-all-the-variables-be-seen-as-a-crude-form-of-pca [Cited 28 Oct 2020].Search in Google Scholar

19. Clerico, A, Ripoli, A, Zucchelli, GC, Plebani, M. Harmonization protocols for thyroid stimulating hormone (TSH) immunoassays: different approaches based on the consensus mean value. Clin Chem Lab Med 2015;53:377–82https://www.degruyter.com/doi/10.1515/cclm-2014-0586.10.1515/cclm-2014-0586Search in Google Scholar PubMed

20. Tate, JR, Bunk, DM, Christenson, RH, Barth, JH, Katrukha, A, Noble, JE, et al.. Evaluation of standardization capability of current cardiac troponin I assays by a correlation study: results of an IFCC pilot project. Clin Chem Lab Med 2015;53:677–90https://www.degruyter.com/doi/10.1515/cclm-2014-1197.10.1515/cclm-2014-1197Search in Google Scholar PubMed

21. Manzotti, C, Casazza, G, Stimac, T, Nikolova, D, Gluud, C. Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy. Cochrane Hepato-Biliary Group, editor. Cochrane Database Syst Rev 2019:2. Art. No.: CD012546. Available from: http://doi.wiley.com/10.1002/14651858.CD012546.pub2 [Cited 17 Oct 2020].10.1002/14651858.CD012546.pub2Search in Google Scholar PubMed PubMed Central


Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2021-0496).


Received: 2021-04-26
Accepted: 2021-06-22
Published Online: 2021-08-06
Published in Print: 2021-11-25

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?
  4. Mathematical recalibration of total bile acids: comparing the incomparable?
  5. Reviews
  6. Could metabolomics drive the fate of COVID-19 pandemic? A narrative review on lights and shadows
  7. Low free-T3 serum levels and prognosis of COVID-19: systematic review and meta-analysis
  8. Opinion Paper
  9. Pancreatic lipase: why laboratory community does not take enough care of this clinically important test?
  10. General Clinical Chemistry and Laboratory Medicine
  11. The BACH project protocol: an international multicentre total Bile Acid Comparison and Harmonisation project and sub-study of the TURRIFIC randomised trial
  12. Comparability of 11 different equations for estimating LDL cholesterol on different analysers
  13. Streamlined three step total vitamin C analysis by HILIC-UV for laboratory testing
  14. Hematology and Coagulation
  15. Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?
  16. Cancer Diagnostics
  17. Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics
  18. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference
  19. Cardiovascular Diseases
  20. Identification of macrotroponin T: findings from a case report and non-reproducible troponin T results
  21. Diabetes
  22. Impact of optimizing pre-analytical phase on the diagnosis of gestational diabetes and related outcomes
  23. Infectious Diseases
  24. Daily monitoring of viral load measured as SARS-CoV-2 antigen and RNA in blood, IL-6, CRP and complement C3d predicts outcome in patients hospitalized with COVID-19
  25. Alternative detection of SARS-CoV-2 RNA by a new assay based on mass spectrometry
  26. Performance evaluation of an automated SARS-CoV-2 Ag test for the diagnosis of COVID-19 infection on nasopharyngeal swabs
  27. Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
  28. Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign
  29. Letters to the Editors
  30. Effects of various pre-analytical conditions on blood-based biomarkers of Alzheimer’s disease
  31. Stability of lactate in venous blood gas and sodium fluoride-potassium oxalate plasma: a 6-year retrospective database analysis
  32. Validation of the Fujirebio Lumipulse G1200 aldosterone assay for measurements during adrenal venous sampling for primary hyperaldosteronism
  33. The new Roche Elecsys TSH assay conforms with current IFCC C-STFT standards
  34. Development of an inverse-PCR approach for characterization of the major BCR-ABL1 breakpoint sequences on genomic DNA: proof of concept
  35. Antiphospholipid antibodies quantification using ALBIA technology: how to define an optimal cutoff?
  36. Simultaneous occurrence of EDTA-dependent lymphoagglutination and agglutination of myeloid cells in a patient with chronic myelomonocytic leukemia
  37. NT-proBNP use in old patients and the impact of the selected threshold value: a big data analysis
  38. Congress Abstracts
  39. 53rd National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC – Laboratory Medicine)
Downloaded on 30.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2021-0496/html
Scroll to top button